Update 3rd October 2022
An announcement from Viewpoint Molecular Targeting indicates the U.S. Food and Drug Administration (FDA) has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2-positive unresectable or metastatic neuroendocrine tumors (NETs) (including GEP-NETs or bronchial NETs and pheochromocytomas and paragangliomas).
This does not mean the drug is approved for routine use, it just means the drug development has been given special treatment based on closer collaboration with FDA to ensure a smoother path when required. Clearly the drug still needs to meet FDA criteria along the way. Read the announcement here.
Update 10 September 2021
Edit: We await the results as at 3rd October 2022.
3 years ago, I wrote about an emerging type of peptide receptor radionuclide therapy (PRRT) suggesting it could be next generation. That work continues. It was being labelled with the term “Targeted Alpha-emitter Therapy (TAT)” using “alpha particles”. The current approved types of PRRT use beta particles so is a totally different method. You might be thinking what the differences are and how does it affect me? You can read more in my article PRRT – The Sequel? – Targeted Alpha-emitter Therapy (TAT).
I also wrote about the term THERANOSTICS, a combo term for THERAPY and DIAGNOSTICS. In the same way that you have a theranostic pair in Ga68 PET and Lu177 DOTATATE/DOTATOC, alpha particle therapy will need the same approach in order that specialists know the output from the diagnostic imaging, will have a therapeutic effect using alpha therapy.
So, it is good to see trials emerging along these lines. VMT-𝛼-NET is entering a Phase 1 imaging study followed by a Phase 1 therapy study for neuroendocrine tumours at the University of Iowa.
VMT = Viewpoint Molecular Targeting
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s proprietary technology utilizes lead-212 (i.e. 212Pb mentioned in the TAT article above) to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This ‘theranostic’ approach enables the ability to see the specific tumour and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
VMT-𝛼-NET is designed to deliver powerful alpha particle radiation specifically to the NET, while minimizing risk to normal organs and tissues. In 2019, the University of Iowa was awarded an R01 research grant from the National Cancer Institute (NCI) to prepare for and conduct an image-guided alpha-particle therapy trial of VMT-𝛼-NET for NETs. The first-in-human imaging trial was anticipated to commence in early 2021 but in April 2022, I don’t believe the trial linked below was commenced (to be confirmed). Viewpoint has further been awarded over $4M in the form of Small Business Innovation Research grants from the NCI to advance this cutting-edge treatment to clinical development. Thus, the VMT-𝛼-NET receptor-targeted alpha-particle radiotherapy is positioned to advance a new transformative treatment paradigm for NET patients.
The Company’s melanoma (VMT01) and neuroendocrine tumour (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumours at two leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trials and commercial operations. For more information, please visit the Company’s website viewpointmt.com.
A First-in-human Clinical Trial to Evaluate an Alpha-radiation Imaging Agent
This is the first-in-human study to determine if [203Pb]VMT-α-NET identifies neuroendocrine tumors with SPECT/CT. This is the first step to testing [212Pb]-based alpha radiation therapy in neuroendocrine therapy. Details of this clinical trial can be found here.
General Clinical Trials Disclaimer
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact. If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net
The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan.
Whenever I post about a trial or study, some people get excited without understanding that these new treatments and capabilities can very often take years to come to fruition and it’s also possible that clinical trials can be halted, or that national approval agencies will not approve the final product. Plus, not everyone will be eligible, so always check the exclusion and inclusion criteria in the relevant clinical trials document. Please bear that in mind when reading studies/clinical trials posted on RonnyAllan.NET
Subscribe to my newsletter
Top 10 Posts & Pages in the last 48 hours (auto updates)
Thanks for reading.
Sign up for my newsletters – Click Here
Check out my Glossary of Terms – click here
Please Share this post for Neuroendocrine Cancer awareness and to help another patient
This should be of interest, particularly to Canadians. (Not to be confused with 18F-FDG which is a different scan). For people waiting for imaging tests
Wilko playing at his last show. Oct 2022 in London. Aged 75. RIP Wilko Johnson – Neuroendocrine Cancer I have been following Wilko’s cancer story
Definitions – the differences between Hereditary vs Familial vs Genetic Disorders I wanted to start with these definitions because people may unintentionally use these three
I’m still here I was 54 years and 9 months old at diagnosis on 26th July 2010. For the first few months, I had no
Background to Diet and Nutrition This is clearly an important topic for many patients. In my group, it is the 12th most common topic out